Associate Professor Sue Henshall
Senior Research Fellow; Group leader, Cancer Research Program, Garvan Institute of Medical Research; Assistant Professor (Conjoint) Georgetown University, USA; Associate Professor (Adjunct), Faculty of Medicine, The University of New South Wales
Email: s.henshall 'at' garvan.org.au
Research Group: Prostate Cancer
Education
1994-1995 Post-doctoral Fellow, Department of Pathology &
Infectious Diseases, Royal Veterinary College, University of London, UK
1994 Ph.D. University of Adelaide, SA
1988 B.Sc (Hons) University of Adelaide, SA
Awards
2002-2004 Prostate Cancer Foundation of Australia Inaugural Research Fellow, Cancer Research Program, Garvan Institute of Medical Research, Sydney, Australia
1989-1994 Dawes Scholar, Hepatitis Research Laboratory, Division of Medical Virology, Institute of Medical and Veterinary Science, Royal Adelaide Hospital, Adelaide, Australia
Publications
Rasiah KK, Kench JG, Gardiner-Garden M, Biankin AV, Golovsky D, Brenner PC, Kooner R, O'Neil GF, Turner JJ, Delprado W, Lee CS, Brown DA, Breit SN, Grygiel JJ, Horvath LG, Stricker PD, Sutherland RL, Henshall SM. Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis. Cancer Epidemiol Biomarkers Prev 2006; 15:711-716.
Henshall SM, Horvath LG, Quinn DI, Eggleton SA, Grygiel JJ, Stricker PD, Biankin AV, Kench JG, Sutherland RL. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. Journal of the National Cancer Institute 2006; 98:1420-1424.
Segara D, Biankin AV, Kench JG, Langusch CC, Dawson AC, Skalicky DA, Gotley DC, Coleman MJ, Sutherland RL, Henshall SM. Expression of HOXB2, a retinoic acid signaling target in pancreatic cancer and pancreatic intraepithelial neoplasia. Clinical Cancer Research 2005; 11:3587-96.
Horvath LG, Henshall SM, Kench JG, Saunders DN, Lee C-S, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ, Sutherland RL. Membranous expression of secreted frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC-3 cellular proliferation in vitro. Clinical Cancer Research 2004; 10:615-625.
Bhaskar V, Law DA, Ibsen E, Breinberg D, Cass KM, DuBridge RB, Evangelista F, Henshall SM, Hevezi P, Miller JC, Pong M, Powers R, Senter P, Stockett D, Sutherland RL, von Freeden-Jeffry U, Willhite D, Murray R, Afar DEH, Ramakrishnan V. E-selectin up-regulation allows for targeted drug delivery in prostate cancer. Cancer Research 2003; 63:6387-6394.
Cagiannos I, Karakiewicz P, Eastham JA, Ohori M, Rabbani F, Gerigk C, Reuter V, Graefen M, Hammerer PG, Erbersdobler A, Huland H, Kupelian P, Klein E, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Morash CG, Scardino PT, Kattan MW. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. Journal of Urology 2003; 170:1798-1803.
Henshall SM, Afar DEH, Hiller J, Horvath LG, Quinn DI, Rasiah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, Stricker PD, Scher HI, Grygiel JJ, Agus DB, Mack DH, Sutherland RL. Survivial analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Research 2003; 63:4196-4203.
Henshall SM, Afar DEH, Rasiah KK, Horvath LG, Gish K, Caras I, Ramakrishnan V, Wong M, Jeffry U, Kench JG, Quinn DI, Turner JJ, Delprado W, Lee C-S, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ, Mack DH, Sutherland RL. Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene 2003; 22:6005-6012.
Quinn DI, Henshall SM, Brenner PC, Kooner R, Golovsky D, O'Neill GF, Turner JJ, Delprado W, Grygiel JJ, Sutherland RL, Stricker PD. Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy. Cancer 2003; 97:1884-1893.
Afar DEH, Bhaskar V, Ibsen E, Breinberg D, Henshall SM, Kench JG, Drobniak M, Powers R, Wong M, Evangelista F, O'Hara C, Powers D, Dubridge R, Caras I, Winter R, Solvasen N, Anderson T, Stricker PD, Cordon-Cardo C, Scher HI, Grygiel JJ, Sutherland RL, Murray R, Ramakrishnan V, Law D. Pre-clinical validation of anti-TMEFF2-Auristatin E-conjugated antibodies in the treatment of prostate cancer. Molecular Cancer Therapy 2004; 3:921-932.
